Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide

被引：0
|
作者：
Raza, A [1 ]
Lisak, L [1 ]
Little, L [1 ]
Andrews, C [1 ]
Meyer, P [1 ]
Ekbal, M [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Canc Inst, Chicago, IL USA
来源：
EXPERIMENTAL HEMATOLOGY | 2000年 / 28卷 / 07期
关键词：
D O I：
10.1016/S0301-472X(00)00408-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
228
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [1] Lenalidomide-induced cytopenias: Relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    Maciejewski, Jwoslaw P.
    Giagounidis, Aristoteles
    Wride, Kenton
    Knight, Robert D.
    Raza, Azra
    List, Alan F.
    BLOOD, 2007, 110 (11) : 252A - 252A
  • [2] Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Qawi, H
    Naseer, OB
    Dar, S
    Lisak, L
    Andric, T
    Ali, SI
    Quadri, M
    Ahmed, B
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    BLOOD, 1998, 92 (10) : 631A - 631A
  • [3] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 274B
  • [4] Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, LA
    Tahir, S
    Billmeier, JM
    Willmann, HS
    Alvi, MI
    Bellak, DJ
    Gezer, S
    Venugopal, P
    BLOOD, 2002, 100 (11) : 340B - 340B
  • [5] Arsenic trioxide (Trisenox®) with/without thalidomide in patients with myelodysplastic syndromes (MDS) produces hematologic improvement (HI).
    Raza, A
    Lisak, L
    Billmeier, J
    Akbar, S
    Washeed, K
    Mumtaz, M
    Reddy, P
    Galili, N
    BLOOD, 2004, 104 (11) : 261B - 262B
  • [6] Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Dutt, D
    Dean, L
    Fantroy, L
    Syed, E
    Gezer, S
    Hsu, WT
    Goldberg, C
    Loew, J
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 273B
  • [7] Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide.
    Alvi, S
    Shaikh, M
    Anthwal, S
    Shaher, A
    Tamoseviciene, D
    Novick, A
    Reddy, P
    Allampallam, K
    Hsu, WT
    Galili, N
    Borok, RZ
    Raza, A
    BLOOD, 2001, 98 (11) : 352A - 352A
  • [8] Thalidomide for the treatment of patients with myelodysplastic syndromes
    Strupp, C
    Germing, U
    Aivado, M
    Misgeld, E
    Haas, R
    Gattermann, N
    LEUKEMIA, 2002, 16 (01) : 1 - 6
  • [9] Thalidomide for the treatment of patients with myelodysplastic syndromes
    C Strupp
    U Germing
    M Aivado
    E Misgeld
    R Haas
    N Gattermann
    Leukemia, 2002, 16 : 1 - 6
  • [10] Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS)
    Candoni, A.
    Raza, A.
    Galili, N.
    Simeone, E.
    Buttignol, S.
    Silvestri, F.
    Fanin, R.
    LEUKEMIA RESEARCH, 2007, 31 : S119 - S119
12345